Skip to main content
. 2018 Oct 26;19(11):3352. doi: 10.3390/ijms19113352

Figure 3.

Figure 3

SDS-PAGE of Native and Se-conjugated mAbs under reducing conditions followed by Coomassie Blue R-250 staining. Lane 1: Kadcyla® 20 µg; Lane 2: Marker; Lane 3: BV 5 µg; Lane 4: BV 10 µg; Lane 5: BV 20 µg; Lane 6: Se-BV 5 µg; Lane 7: Se-BV 10 µg; Lane 8: Se-BV 20 µg; Lane 9: TZ 5 µg; Lane 10: TZ 10 µg; Lane 11: TZ 20 µg, Lane 12: Se-TZ 10 µg; Lane 13: Se-TZ 20 µg; Lane 14: Gamma globulin 20 µg. (BV: Bevacizumab, Se-BV: Selenobevacizumab, TZ: Trastuzumab, Se-TZ: Selenotrastuzumab).